Patient Registry of Roflumilast In Real Life
NCT02015767 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1950
Last updated 2017-06-23
Summary
A patient registry to capture real life data and demonstrate the performance of roflumilast (Daxas®) in a standard clinical practice.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
AstraZeneca AstraZeneca · AstraZeneca
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-02-01
- Primary Completion
- 2016-08-31
- Completion
- 2016-08-31
Countries
- Bulgaria
- Greece
- Hong Kong
- Norway
- Slovakia
- South Korea
Study Locations
More Related Trials
-
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)
NCT01329029 ·Status: COMPLETED ·Phase: PHASE4
-
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
NCT01443845 ·Status: COMPLETED ·Phase: PHASE4
-
Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease
NCT02419872 ·Status: COMPLETED
-
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
NCT00297115 ·Status: COMPLETED ·Phase: PHASE3
-
Assessment of Early Outcomes of Roflumilast in Patients With Non Cystic Fibrosis Bronchiectasis
NCT04090294 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08)
NCT00246935 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease
NCT01595750 ·Status: UNKNOWN ·Phase: PHASE4
-
Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease
NCT01509677 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice.
NCT05426915 ·Status: UNKNOWN
-
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
NCT00076089 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
NCT01473758 ·Status: TERMINATED ·Phase: PHASE2
-
Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients
NCT01580748 ·Status: UNKNOWN ·Phase: PHASE2
-
Roflumilast Safety Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily
NCT01849341 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)
NCT00242294 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:
NCT01313494 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
NCT00363896 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD
NCT02165826 ·Status: COMPLETED ·Phase: PHASE3
-
A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients
NCT02671942 ·Status: TERMINATED ·Phase: PHASE2
-
Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD)
NCT01630200 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD
NCT02097992 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)
NCT00297102 ·Status: COMPLETED ·Phase: PHASE3
-
AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
NCT01215279 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
NCT01023516 ·Status: COMPLETED ·Phase: PHASE2
-
A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.
NCT00468975 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)
NCT00313209 ·Status: COMPLETED ·Phase: PHASE3